Sohn Seil, Chung Chun Kee, Sohn Moon Jun, Chang Ung-Kyu, Kim Sung Hwan, Kim Jinhee, Park Eunjung
Department of Neurosurgery, Seoul National University College of Medicine, 101 Daehak-no, Jongno-gu, Seoul, 110-744, Korea.
J Neurooncol. 2014 Aug;119(1):121-8. doi: 10.1007/s11060-014-1455-9. Epub 2014 May 3.
The aim of this multicenter, matched- pair study was to compare the outcome of stereotactic radiosurgery (SRS) with that of external radiation therapy (RT) when used as a primary treatment in spine metastasis from renal cell carcinoma (RCC). From 2005 to 2012, 13 patients underwent SRS as a primary treatment in spine metastasis from RCC. Thirteen patients who underwent RT as the primary treatment of RCC spine metastasis were paired with the SRS patients based on age, number of spine metastasis, time interval from original tumor diagnosis to spine metastasis, Eastern Cooperative Oncology Group status, and year of treatment. The primary outcomes of interest were pain relief and progression free survival. Secondary outcomes were treatment toxicities and need for further treatment. The perioperative VAS score decrease was larger in the SRS group than that in the RT group (P = 0.04). More SRS patients had complete or partial pain relief although the difference was not significant. There was a significant difference in progression free survival between the two groups (P = 0.01). The percentage of patients with toxicities was 38.5 % (5/13) in the SRS group and 53.9 % (7/13) in the RT group, but the difference was not significant. There were 2 SRS patients and 3 RT patients who received further intervention at the index segment. This study showed that, when performed as a primary treatment in spine metastasis from RCC, SRS provides relatively better pain relief and better local control than that obtained from RT.
这项多中心配对研究的目的是比较立体定向放射外科治疗(SRS)与外照射放疗(RT)作为肾细胞癌(RCC)脊柱转移瘤主要治疗方法时的疗效。2005年至2012年,13例患者接受了SRS作为RCC脊柱转移瘤的主要治疗方法。将13例接受RT作为RCC脊柱转移瘤主要治疗方法的患者,根据年龄、脊柱转移瘤数量、从原发肿瘤诊断到脊柱转移的时间间隔、东部肿瘤协作组状态和治疗年份,与接受SRS治疗的患者进行配对。主要关注的结果是疼痛缓解和无进展生存期。次要结果是治疗毒性和进一步治疗的需求。SRS组围手术期视觉模拟评分(VAS)的下降幅度大于RT组(P = 0.04)。虽然差异不显著,但更多接受SRS治疗的患者实现了完全或部分疼痛缓解。两组之间的无进展生存期存在显著差异(P = 0.01)。SRS组毒性患者的百分比为38.5%(5/13),RT组为53.9%(7/13),但差异不显著。有2例接受SRS治疗的患者和3例接受RT治疗的患者在索引节段接受了进一步干预。这项研究表明,当作为RCC脊柱转移瘤的主要治疗方法时,SRS比RT能提供相对更好的疼痛缓解和更好的局部控制。